NetSol Technologies Inc, CEL-SCI Corp, United States Antimony Corporation, Zoomcar Holdings Inc. Read Professor Ari Zoldan's latest article on Investing.com ...

Passive Immunization Strategies of passive immunotherapy have been actively pursued as an alternative to active immunization. Representative studies are described. Taken together, preclinical ...

In broad terms, these approaches have traditionally included passive and active immunotherapies ... It has thus become apparent that successful immunotherapy approaches to the treatment of ...

reinforces the best-in-class characteristics of our clinically validated anti-a-syn active immunotherapy for the treatment of ...

A new drug strategy that regulates the tumor immune microenvironment may transform a tumor that resists immunotherapy into a ...

But a new study has shown that an existing immunotherapy could stop scar tissue formation after heart attacks. When the heart sustains an injury, such as a heart attack, the damaged tissue often ...

Encouraging Preclinical Data: Decoy20 has produced efficacy in preclinical studies across a variety of tumor types and in combination with four different classes of existing drugs, demonstrating both ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges ...

Immunotherapy has become the most promising strategy for treating cancer, but its effectiveness is still very uneven. In the month of breast cancer, the most common tumor in women—almost 2.5 ...

Immunotherapy research offers new hope for children with primary liver carcinomas Aug 30, 2024 Cholesterol-lowering therapy may hinder aggressive type of colorectal tumor ...

Jonathan Fisher works for University College London and is an inventor on patents pertaining to gamma-delta T cell immunotherapy. In the past 5 years he has received research funding from UKRI ...